About this trial
In order to tackle the unmet needs in chronic HBV infection, a consortium of clinical partners has gathered to establish a registry for patients with hepatitis B mono- and co-infections. The partners will build up a European-wide registry to be able to stratify patients for upcoming clinical trials.
Extensive analyses of virus and host-specific parameters are to be carried out from these patients. The knowledge gained thereby should contribute to a better understanding of the HBV control and enable patient stratification with regard to immunomodulatory therapies.
Furthermore, hepatitis B patients are to be identified who are willing to participate in future studies to investigate immunotherapies to cure HBV infections (e.g. therapeutic vaccines).
Eligibility criteria
Qualifiers
Hepatitis B Virus Infection
confirmed chronic hepatitis B virus infection: HBsAg positive for at least 1 year prior inclusion
HBeAg status documented for at least 6 months
Disqualifiers
age >70 years
co-infection with HIV, HCV (RNA positive),
clinically relevant concomitant liver diseases (ALD, NASH, Haemochromatosis, Autoimmune hepatitis, AT1, Wilson's disease, primary biliary cirrhosis etc.)
significant comorbidities (e.g. malignancies)
Trial design
Treatments tested in this trial
- No intervention
Treatment groups
Sponsors and collaborators
Hannover Medical School
Lead sponsor
European Union
Collaborator
German Center for Infection Research
Collaborator
German Liver Foundation (DLS)
Collaborator